Centessa Pharmaceuticals plc Income Statement
CNTA / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Centessa Pharmaceuticals plc reported $15M in revenue and $198M in net loss for FY2025. Revenue increased 118.9% from FY2023 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $15.0M | $0 | $6.9M | $0 | - | - | - |
| SG&A Expense | $50.5M | $50.8M | $53.7M | $55.2M | $42.9M | $1.1M | $790.0K |
| R&D Expense | $172.2M | $150.2M | $124.4M | $155.1M | $95.7M | $9.3M | $4.3M |
| Operating Income | -$207.7M | -$201.1M | -$171.3M | -$212.3M | -$374.1M | -$10.4M | -$5.1M |
| Interest Expense | - | - | $9.9M | $7.3M | - | - | - |
| Income Tax | $1.8M | $2.8M | -$25.1M | -$747.0K | $114.0K | $0 | $0 |
| Net Income | -$197.5M | -$235.8M | -$151.1M | -$216.2M | -$381.1M | -$10.7M | -$5.1M |
| EPS (Basic) | -$1.46 | -$2.06 | -$2.31 | -$2.31 | -$5.07 | - | - |
| EPS (Diluted) | -$1.46 | -$2.06 | -$2.31 | -$2.31 | -$5.07 | - | - |
| Shares Outstanding | 149.2M | 132.6M | 94.8M | 93.4M | 75.2M | - | - |
| Operating Margin | -1384.6% | - | -2499.4% | - | - | - | - |
| Profit Margin | -1316.9% | - | -2204.7% | - | - | - | - |